The purpose of this study is to see how results of nerve tests change in people with urothelial cancer who receive treatment with enfortumab vedotin (EV)

Inclusion Criteria:

• Written informed consent by and HIPAA authorization for release of personal health information obtained from the research participant.
• Able to speak and read English to a sufficient level of fluency to provide informed consent and complete the study questionnaires.
• Age ≥ 18 years at the time of consent.
• ECOG Performance Status of ≤ 3 within 28 days prior to consent.
• Histological or cytologically confirmed urothelial carcinoma.
• Patients must be planned to start systemic therapy with enfortumab vedotin
• At time of enrollment, patients must be planned to start enfortumab with or without pembrolizumab

Exclusion Criteria:

Subjects meeting any of the criteria below may not participate in the study:

• Inability of the subject to understand and comply with study procedures.
• Having previously received enfortumab vedotin
• Students/employees of the study institution, pregnant women, prisoners, and institutionalized individuals (to prevent enrollment of vulnerable subjects).

Since EV will be given per standard of care, we have not included inclusion criteria relevant to the safety of administering EV itself, since that will be left to the discretion of the treating clinician in a real-world, usual care setting, as is standard practice for non-therapeutic studies.

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.